SCHEMBL26906941

SCHEMBL26906941

COc1cc(N2CCC(N3CCN(C4CC4)CC3)CC2)c(C)cc1Nc1ncc(Br)c(Nc2ccc(F)cc2NS(C)(=O)=O)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.60
▸ CHEK1 O14757 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ CCNT1 O60563 1/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ RET P07949 1/20 0.53
▸ MET P08581 1/20 0.53
▸ ROS1 P08922 1/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ KIT P10721 1/20 0.53
▸ PIM1 P11309 1/20 0.53
▸ PDGFRA P16234 1/20 0.53
▸ FER P16591 1/20 0.53
▸ EPHA1 P21709 1/20 0.53
▸ MAPK3 P27361 1/20 0.53
▸ EPHB2 P29323 1/20 0.53
▸ AXL P30530 1/20 0.53
▸ MAPK8 P45983 1/20 0.53
▸ CDK9 P50750 1/20 0.53
▸ PKD1 P98161 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26906514 0.94 EGFR (0.66) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26906769 0.93 EGFR (0.55) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26906798 0.91 EGFR (0.66) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26906884 0.90 EGFR (0.59) EGFR
SCHEMBL26906533 0.90 EGFR (0.63) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26907006 0.89 EGFR (0.63) EGFR
SCHEMBL27075982 0.89 EGFR (0.66) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26906530 0.86 EGFR (0.67) EGFRCHEK1AURKACCNT1JAK2
SCHEMBL26906912 0.86 EGFR (0.48) EGFR
SCHEMBL27091531 0.85 EGFR (0.71) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN claimed
WO-2022211573-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 테라펙스 2022-10-06 — — WO claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN disclosed
WO-2022211573-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 테라펙스 2022-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 EGFR 1/4885CHEK1 232/4885AURKA 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback